Case number 2023-2218
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 11, 2025 | 160 | Notice from the U.S. Supreme Court regarding application for an extension of time within which to file a petition for a writ of certiorari. [1098310] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 06/24/2025 04:50 PM] (3) |
| Apr 1, 2025 | 159 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [1079432] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 04/01/2025 09:28 AM] (2) |
| Mar 26, 2025 | 158 | Letter from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. Letter to Clerk of Court to stay issuance of Mandate. Service: 03/26/2025 by email. [1078250] [23-2218] [Ronald Daignault] [Entered: 03/26/2025 03:46 PM] (1) |
| Mar 25, 2025 | 157 | ORDER filed. Denying motion to reconsider [129] ; denying motion for leave to file a reply[134]; denying the petition for panel rehearing and rehearing [136] . Please see the order for full and complete details. By: Per Curiam. Service as of this date by the Clerk of Court. [1078016] [MVH] [Entered: 03/25/2025 05:07 PM] (3) |
| Mar 14, 2025 | 156 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation to Doc No. [155]. Service: 03/14/2025 by email. [1075342] [23-2218] [Deanne Maynard] [Entered: 03/14/2025 10:18 AM] (3) |
| Mar 11, 2025 | 155 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 03/11/2025 by email. [1074692] [23-2218] [William Rakoczy] [Entered: 03/11/2025 07:50 PM] (39) |
| Mar 7, 2025 | 154 | 13 paper copies of Doc. No. [153] received from Appellant Novartis Pharmaceuticals Corporation. [1073829] [MVH] [Entered: 03/07/2025 11:54 AM] (0) |
| Mar 5, 2025 | 153 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation to Doc No. [136], [136]. Service: 03/05/2025 by email. [1073378] [23-2218] [Deanne Maynard] [Entered: 03/05/2025 04:40 PM] (28) |
| Mar 3, 2025 | 152 | 6 paper copies of Doc. No. [151] received from Amicus Curiae Association for Accessible Medicines. [1073353] [VDW] [Entered: 03/05/2025 04:02 PM] (0) |
| Feb 27, 2025 | 150 | ORDER filed granting motion for leave for Association for Accessible Medicines to file amicus brief on rehearing petition [149]. By: Per Curiam. Service as of this date by the Clerk of Court. [1071967] [MVH] [Entered: 02/27/2025 12:59 PM] (2) |
| Feb 27, 2025 | 151 | AMICUS BRIEF FILED on Petition by Association for Accessible Medicines. Service: 02/24/2025 by email. The filer is directed to submit the appropriate number of copies within two days. [1071968] [MVH] [Entered: 02/27/2025 01:03 PM] (23) |
| Feb 24, 2025 | 147 | Corrected Entry of Appearance for Robert V. Cerwinski; Lora M. Green; Michael B. Cottler; Aviv A. Zalcenstein as counsel for Association for Accessible Medicines. Service: 02/24/2025 by email. [1071127] [23-2218] [Robert Cerwinski] [Entered: 02/24/2025 05:46 PM] (2) |
| Feb 24, 2025 | 148 | Corrected Certificate of Interest for Association for Accessible Medicines. Service: 02/24/2025 by email. [1071128] [23-2218] [Robert Cerwinski] [Entered: 02/24/2025 05:48 PM] (3) |
| Feb 24, 2025 | 149 | MOTION of Association for Accessible Medicines for leave to file amicus brief in support of MSN Pharmaceuticals, Inc. on petition for panel rehearing [136], petition for en banc rehearing [136]. Service: 02/24/2025 by email. [1071129] [23-2218] [Robert Cerwinski] [Entered: 02/24/2025 05:51 PM] (34) |
| Feb 21, 2025 | 146 | NOTICE OF NON-COMPLIANCE: The submissions of Movant Association for Accessible Medicines, Entry of Appearance; Motion for Leave to File Brief as Amicus Curiae (and Proposed Brief) [145], [143], are not in compliance with the rules of this court (see attached). Compliant documents due on 02/28/2025. Service as of this date by the Clerk of Court. [1070512] [MVH] [Entered: 02/21/2025 07:59 AM] (2) |
| Feb 20, 2025 | 143 | Corrected Entry of Appearance for Robert V. Cerwinski; Lora M. Green; Michael B. Cottler; Aviv A. Zalcenstein as counsel for Association for Accessible Medicines. Service: 02/20/2025 by email. [1070484] [23-2218]. This document is non-comlpiant. See Doc. No. [146] [Robert Cerwinski] [Entered: 02/20/2025 05:51 PM] (2) |
| Feb 20, 2025 | 144 | Corrected Certificate of Interest for Association for Accessible Medicines. Service: 02/20/2025 by email. [1070485] [23-2218] [Robert Cerwinski] [Entered: 02/20/2025 05:53 PM] (3) |
| Feb 20, 2025 | 145 | MOTION of Association for Accessible Medicines for leave to file amicus brief in support of MSN Pharmaceuticals, Inc. on petition for panel rehearing [136], petition for en banc rehearing [136]. Service: 02/20/2025 by email. [1070491] [23-2218]. This document is non-compliant. See Doc. No. [146] [Robert Cerwinski] [Entered: 02/20/2025 06:05 PM] (34) |
| Feb 19, 2025 | 141 | NOTICE OF NON-COMPLIANCE: The submissions of Association for Accessible Medicines, Entry of Appearance, Certificate of Interest, and Motion for Leave to File Brief as Amicus Curiae (and Proposed Brief) [140], [139], [138], are not in compliance with the rules of this court (see attached). Compliant documents due on 02/26/2025. Service as of this date by the Clerk of Court. [1070066] [MVH] [Entered: 02/19/2025 12:01 PM] (2) |
| Feb 19, 2025 | 142 | The court invites a response from Appellant Novartis Pharmaceuticals Corporation to the petition [136]. Response due 03/05/2025. Service as of this date by the Clerk of Court. [1070079] [MVH] [Entered: 02/19/2025 12:37 PM] (1) |
| Feb 18, 2025 | 138 | Entry of Appearance for Robert V. Cerwinski; Lora M. Green; Michael B. Cottler; Aviv A. Zalcenstein as counsel for Association for Accessible Medicines. Service: 02/18/2025 by email. [1069921] [23-2218]. This document is non-compliant. See Doc. No. [141] [Robert Cerwinski] [Entered: 02/18/2025 06:40 PM] (2) |
| Feb 18, 2025 | 139 | Certificate of Interest for Association for Accessible Medicines. Service: 02/18/2025 by email. [1069922] [23-2218]. This document is non-compliant. See Doc. No. [141] [Robert Cerwinski] [Entered: 02/18/2025 06:42 PM] (3) |
| Feb 18, 2025 | 140 | MOTION of Association for Accessible Medicines for leave to file amicus brief in support of MSN Pharmaceuticals, Inc. on petition for panel rehearing [136], petition for en banc rehearing [136]. Service: 02/18/2025 by email. [1069923] [23-2218]. This document is non-compliant. See Doc. No. [141] [Robert Cerwinski] [Entered: 02/18/2025 06:49 PM] (34) |
| Feb 13, 2025 | 137 | 13 paper copies of Doc. No. [136] received from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. [1069137] [VDW] [Entered: 02/13/2025 03:02 PM] (0) |
| Feb 10, 2025 | 136 | Petition for panel rehearing, for en banc rehearing filed by Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 02/10/2025 by email. [1068320] [23-2218] [William Rakoczy] [Entered: 02/10/2025 04:54 PM] (50) |
| Feb 3, 2025 | 134 | MOTION of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. for leave to file a response/reply to Doc. No. [132]. Service: 02/03/2025 by email. [1065996] [23-2218] [William Rakoczy] [Entered: 02/03/2025 10:37 AM] (31) |
| Jan 31, 2025 | 133 | Notice from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. of Intent to File Reply in Support of Motion for Reconsideration and Petition for En Banc Rehearing of January 21, 2025 Order (ECF No. 127). Service: 01/31/2025 by email. [1065745] [23-2218] [Kevin Warner] [Entered: 01/31/2025 01:34 PM] (4) |
| Jan 31, 2025 | 135 | 13 paper copies of Doc. No. [132] received from Appellant Novartis Pharmaceuticals Corporation. [1066015] [VDW] [Entered: 02/03/2025 11:16 AM] (0) |
| Jan 30, 2025 | 132 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation to Doc No. [129], [129], [129]. Service: 01/30/2025 by email. [1065395] [23-2218] [Deanne Maynard] [Entered: 01/30/2025 04:07 PM] (32) |
| Jan 28, 2025 | 131 | ORDER filed. The request for an administrative stay is denied. The motion to expedite is granted to the extent that a response is due on or before 1/30/25. Please see the order for full and complete details. By: Per Curiam. Service as of this date by the Clerk of Court. [1064669] [MVH] [Entered: 01/28/2025 05:07 PM] (3) |
| Jan 23, 2025 | 130 | Notice from Appellant Novartis Pharmaceuticals Corporation of Intent to Respond and Objection to Administrative Stay. Service: 01/23/2025 by email. [1062716] [23-2218] [Deanne Maynard] [Entered: 01/23/2025 08:20 AM] (7) |
| Jan 22, 2025 | 128 | 13 paper copies of Doc. No. [125] received from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. [1062490] [JCP] [Entered: 01/22/2025 12:52 PM] (0) |
| Jan 22, 2025 | 129 | MOTION of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to reconsider Doc. No. [127], [127], to reconsider en banc Doc. No. [127], [127], to expedite briefing schedule. Service: 01/22/2025 by email. [1062701] [23-2218] [William Rakoczy] [Entered: 01/22/2025 07:55 PM] (48) |
| Jan 21, 2025 | 127 | ORDER filed. The motion to file a reply [124] is granted. The motion to reconsider [115] is granted to the extent that [109] is vacated and [63]; [105] are granted to the extent that MSN Life Sciences Private Ltd. are enjoined, until issuance of the mandate in these appeals, from commercial marketing and sale of their generic version of Entresto. The petition for rehearing [115] is moot. Please see the order for full and complete details. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [1062172] [MVH] [Entered: 01/21/2025 02:51 PM] (4) |
| Jan 18, 2025 | 125 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [124]. Service: 01/18/2025 by email. [1061919] [23-2218] [William Rakoczy] [Entered: 01/18/2025 12:30 PM] (8) |
| Jan 17, 2025 | 122 | 13 paper copies of Doc. No. [115] received from Appellant Novartis Pharmaceuticals Corporation. [1061751] [JCP] [Entered: 01/17/2025 02:39 PM] (0) |
| Jan 17, 2025 | 123 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [115], [115], [115], [115]. Service: 01/17/2025 by email. [1061769] [23-2218] [William Rakoczy] [Entered: 01/17/2025 02:59 PM] (116) |
| Jan 17, 2025 | 124 | MOTION of Appellant Novartis Pharmaceuticals Corporation for leave to file a response/reply to Doc. No. [123]. Service: 01/17/2025 by email. [1061902] [23-2218] [Deanne Maynard] [Entered: 01/17/2025 05:52 PM] (17) |
| Jan 17, 2025 | 126 | REPLY of Appellant Novartis Pharmaceuticals Corporation to response [123]. Service: 01/17/2025 by email. [1062151] [MVH] [Entered: 01/21/2025 02:41 PM] (12) |
| Jan 16, 2025 | 117 | ORDER filed. Any response to [115] is due on or before 3 p.m. on 1/17/25. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [1061337]. This order has been corrected. See Doc. No. [120]--[Edited 01/16/2025 by MVH] [MVH] [Entered: 01/16/2025 12:21 PM] (0) |
| Jan 16, 2025 | 118 | Notice from Appellant Novartis Pharmaceuticals Corporation update on related proceeding. Service: 01/16/2025 by email. [1061471] [23-2218] [Deanne Maynard] [Entered: 01/16/2025 03:22 PM] (1) |
| Jan 16, 2025 | 119 | ORDER filed. MSN Pharmaceuticals, Inc., MSN Laboratories Private Ltd., and MSN Life Sciences Private Ltd. are temporarily enjoined from commercial marketing and sale of their generic version of Entresto until further notice. By: Per Curiam. Service as of this date by the Clerk of Court. [1061508]. This order has been corrected. See Doc. No. [121]--[Edited 01/16/2025 by MVH] [MVH] [Entered: 01/16/2025 04:28 PM] (0) |
| Jan 16, 2025 | 120 | CORRECTED ORDER: Correcting [117] Order that any response to [115] is due on or before 3 p.m. on 1/17/25. Reason(s): to include panel. Service as of this date by the Clerk of Court. [1061530] [MVH] [Entered: 01/16/2025 05:05 PM] (3) |
| Jan 16, 2025 | 121 | CORRECTED ORDER: Correcting [119] Order that MSN Pharmaceuticals, Inc., MSN Laboratories Private Ltd., and MSN Life Sciences Private Ltd. are temporarily enjoined from commercial marketing and sale of their generic version of Entresto until further notice. Reason(s): to include the panel. Service as of this date by the Clerk of Court. [1061533]--[Edited 01/16/2025 by MVH] [MVH] [Entered: 01/16/2025 05:10 PM] (3) |
| Jan 15, 2025 | 115 | MODIFIED ENTRY: Petition for panel rehearing, for en banc hearing. MOTION of Appellant Novartis Pharmaceuticals Corporation to expedite., to reconsider Doc. No. [109] filed by Appellant Novartis Pharmaceuticals Corporation. Service: 01/15/2025 by email. [1061200]--[Edited 01/15/2025 by MVH - Reason: to add reliefs and filing event] [Deanne Maynard] [Entered: 01/15/2025 06:31 PM] (28) |
| Jan 15, 2025 | 116 | Notice from Appellant Novartis Pharmaceuticals Corporation Update on related proceeding. Service: 01/15/2025 by email. [1061212] [23-2218] [Deanne Maynard] [Entered: 01/15/2025 09:00 PM] (1) |
| Jan 14, 2025 | 114 | ORDER filed denying [110] motion to issue mandate; to expedite filed by Novartis Pharmaceuticals Corporation. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [1060774] [MVH] [Entered: 01/14/2025 02:06 PM] (2) |
| Jan 13, 2025 | 112 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [110], [110]. Service: 01/13/2025 by email. [1060253] [23-2218] [Kevin Warner] [Entered: 01/13/2025 12:04 PM] (14) |
| Jan 13, 2025 | 113 | REPLY of Appellant Novartis Pharmaceuticals Corporation to response [112]. Service: 01/13/2025 by email. [1060419] [23-2218] [Deanne Maynard] [Entered: 01/13/2025 04:42 PM] (13) |
| Jan 12, 2025 | 0 | NOVARTIS PHARMACEUTICALS CORPORATION v. TORRENT PHARMA INC. [OPINION] [precedential] (0) |
| Jan 11, 2025 | 110 | MOTION of Appellant Novartis Pharmaceuticals Corporation to issue mandate, to expedite.. Service: 01/11/2025 by email. [1060070] [23-2218] [Deanne Maynard] [Entered: 01/11/2025 01:08 AM] (9) |
| Jan 11, 2025 | 111 | Notice from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. of Intent to File Opposition Response to Novartis' Emergency Motion for Immediate Issuance of This Court's Mandate. Service: 01/11/2025 by email. [1060073] [23-2218] [Kevin Warner] [Entered: 01/11/2025 05:00 PM] (4) |
| Jan 10, 2025 | 106 | OPINION filed for the court by Lourie, Circuit Judge; Prost, Circuit Judge and Reyna, Circuit Judge. Precedential Opinion. Service as of this date by the Clerk of Court. [1059732] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 01/10/2025 10:40 AM] (18) |
| Jan 10, 2025 | 107 | JUDGMENT. AFFIRMED IN PART, REVERSED IN PART. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellee(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [1059743] [23-2218, 23-2220, 23-2221] [MVH] [Entered: 01/10/2025 10:49 AM] (2) |
| Jan 10, 2025 | 108 | Notice from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. of Intent to File Response to Novartis' Motion to Clarify and Continue Injunction and Motion to Expedite Consideration. Service: 01/10/2025 by email. [1059872] [23-2218] [William Rakoczy] [Entered: 01/10/2025 02:23 PM] (6) |
| Jan 10, 2025 | 109 | ORDER filed denying as moot motion for stay pending appeal under Rule 8/18 [63] ;denying [105] motion to clarify and continue the temporary injunection filed by Novartis Pharmaceuticals Corporation. Please see order for full and complete details. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [1059904]. Vacated pursuant to the court's order. See Doc. No. [127] [MVH] [Entered: 01/10/2025 03:08 PM] (3) |
| Jan 9, 2025 | 105 | MOTION of Appellant Novartis Pharmaceuticals Corporation for temporary injunction, to clarify [65] , [65] , [65] , [73] , [73] , [73] , [73] , [73], to expedite.. Service: 01/09/2025 by email. [1059674] [23-2218] [Deanne Maynard] [Entered: 01/09/2025 06:44 PM] (44) |
| Dec 3, 2024 | 104 | ORDER filed. The reply [103] is not accepted, as unauthorized. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [1051150] [MVH] [Entered: 12/03/2024 09:55 AM] (2) |
| Nov 27, 2024 | 103 | REPLY of Appellant Novartis Pharmaceuticals Corporation to response [102]. Service: 11/27/2024 by email. [1050590] [23-2218]. This document is not accepted pursuant to the court's order. See Doc. No. [104] [Deanne Maynard] [Entered: 11/27/2024 04:36 PM] (0) |
| Nov 26, 2024 | 102 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [101]. Service: 11/26/2024 by email. [1050186] [23-2218] [William Rakoczy] [Entered: 11/26/2024 03:08 PM] (3) |
| Nov 19, 2024 | 101 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Novartis Pharmaceuticals Corporation. Service: 11/19/2024 by email. [1048291] [23-2218] [Deanne Maynard] [Entered: 11/19/2024 05:25 PM] (1) |
| Nov 13, 2024 | 100 | Submitted after ORAL ARGUMENT to Panel: Lourie, Circuit Judge; Prost, Circuit Judge and Reyna, Circuit Judge.Arguing counsel: Deanne Maynard for Novartis Pharmaceuticals Corporation and William A. Rakoczy for MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc. and MSN Life Sciences Private Ltd.Oral Argument Audio available here. [1046617] [MJL] [Entered: 11/13/2024 12:59 PM] (0) |
| Nov 1, 2024 | 99 | REPLY of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to response [98]. Service: 11/01/2024 by email. [1044293] [23-2218] [William Rakoczy] [Entered: 11/01/2024 03:21 PM] (2) |
| Oct 31, 2024 | 97 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc. No. [73], [73], [73], [73], [73]. Service: 10/31/2024 by email. [1044064] [23-2218] [Kevin Warner] [Entered: 10/31/2024 06:24 PM] (10) |
| Oct 31, 2024 | 98 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation to Doc. No. [73], [73], [73], [73], [73]. Service: 10/31/2024 by email. [1044084] [23-2218] [Deanne Maynard] [Entered: 10/31/2024 11:28 PM] (6) |
| Oct 23, 2024 | 96 | Clerk's letter to the parties regarding regarding November oral argument. Service as of this date by the Clerk of Court. [1041968] [MJL] [Entered: 10/23/2024 01:51 PM] (1) |
| Oct 18, 2024 | 93 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [91]. Service: 10/18/2024 by email. [1040759] [23-2218]. This document is non-compliant. See Doc. No. [94] [Kevin Warner] [Entered: 10/18/2024 12:40 PM] (3) |
| Oct 18, 2024 | 94 | NOTICE OF NON-COMPLIANCE: The submission of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc., Response [93], is not in compliance with the rules of this court (see attached). Compliant document due on 10/25/2024. Service as of this date by the Clerk of Court. [1040898] [MVH] [Entered: 10/18/2024 04:29 PM] (1) |
| Oct 18, 2024 | 95 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [91]. Service: 10/18/2024 by email. [1040917] [23-2218] [William Rakoczy] [Entered: 10/18/2024 05:51 PM] (3) |
| Oct 17, 2024 | 92 | Clerk's Note to the File: Oral argument will now be held in Courtroom 402. [1040533] [MJL] [Entered: 10/17/2024 03:30 PM] (0) |
| Oct 16, 2024 | 91 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Novartis Pharmaceuticals Corporation. Service: 10/16/2024 by email. [1040193] [23-2218] [Deanne Maynard] [Entered: 10/16/2024 03:28 PM] (39) |
| Sep 20, 2024 | 90 | Clerk's Note to the File: Oral argument in 23-2218 and 24-2211 will now take place before Panel 2411M. [1033898] [23-2218, 24-2211] [MJL] [Entered: 09/20/2024 04:09 PM] (0) |
| Sep 12, 2024 | 87 | ORDER filed revising the official caption as reflected in this order; The motions are granted, and Appeal No. 2023-2218 ECF No. 84 at 8-9 and Appeal No. 2024-2211 ECF No. 55 at 7-8 are accepted for filing. (Per Curiam). Service as of this date by the Clerk of Court. [1031654] [23-2218, 24-2211] [LMS] [Entered: 09/12/2024 11:04 AM] (3) |
| Sep 12, 2024 | 88 | ORDER filed; Appellants are directed to file a bond in the district court in an amount, and subject to terms and conditions, deemed appropriate by the district court. (Per Curiam). Service as of this date by the Clerk of Court. [1031662] [23-2218, 24-2211] [LMS] [Entered: 09/12/2024 11:20 AM] (3) |
| Sep 12, 2024 | 89 | Entry of Appearance for William A. Rakoczy; Kevin E. Warner as counsel for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 09/05/2024 by email. [1031819] [MVH] [Entered: 09/12/2024 03:46 PM] (2) |
| Sep 6, 2024 | 85 | Response to notice of oral argument from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 09/06/2024 by email. [1030670] [23-2218] [Kevin Warner] [Entered: 09/06/2024 04:27 PM] (1) |
| Sep 6, 2024 | 86 | Response to notice of oral argument from Appellant Novartis Pharmaceuticals Corporation. Service: 09/06/2024 by email. [1030693] [23-2218] [Deanne Maynard] [Entered: 09/06/2024 05:18 PM] (1) |
| Sep 5, 2024 | 84 | MOTION of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. for leave to file entry of appearance for William A. Rakoczy; Kevin E. Warner. Service: 09/05/2024 by email. [1030405] [23-2218] [Kevin Warner] [Entered: 09/05/2024 05:33 PM] (9) |
| Sep 4, 2024 | 83 | Confidential Defendants-Appellees Corrected Reply In Support Of Its Bond Request filed by Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. corresponding to Doc. No. [79]. Service: 09/04/2024 by email. [1029842] [23-2218] [Ronald Daignault] [Entered: 09/04/2024 12:26 PM] (0) |
| Aug 30, 2024 | 81 | NOTICE OF NON-COMPLIANCE: The submission of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc., Confidential Reply in Support of Bond [80], is not in compliance with the rules of this court (see attached). Compliant document due on 09/04/2024. Service as of this date by the Clerk of Court. [1029137] [GWK] [Entered: 08/30/2024 12:25 PM] (2) |
| Aug 30, 2024 | 82 | NOTICE OF NON-COMPLIANCE: The submission of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc., Confidential Reply in Support of Bond Request [80], is not in compliance with the rules of this court (see attached). Compliant document due on 09/04/2024. Service as of this date by the Clerk of Court. [1029174] [MVH] [Entered: 08/30/2024 01:01 PM] (2) |
| Aug 29, 2024 | 79 | REPLY of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to response [68], response [76]. Service: 08/29/2024 by email. [1029008] [23-2218] [Ronald Daignault] [Entered: 08/29/2024 11:38 PM] (18) |
| Aug 29, 2024 | 80 | Confidential Defendants-Appellees Reply In Support Of Its Bond Request filed by Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. corresponding to Doc. No. [79]. Service: 08/29/2024 by email. [1029009] [23-2218] This document is non-compliant. See Doc No. [81]. This document is non-compliant. See Doc. No. [82] [Ronald Daignault] [Entered: 08/29/2024 11:51 PM] (0) |
| Aug 28, 2024 | 78 | Official caption revised to reflect the non-participation of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. (see attached). Service as of this date by the Clerk of Court. [1028589] [MVH] [Entered: 08/28/2024 04:39 PM] (3) |
| Aug 26, 2024 | 75 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation and Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. to Doc. No. [72], [72], [72], [72], [72]. Service: 08/26/2024 by email. [1027734] [23-2218] [Deanne Maynard] [Entered: 08/26/2024 04:40 PM] (9) |
| Aug 26, 2024 | 76 | RESPONSE of Appellant Novartis Pharmaceuticals Corporation to Doc. No. [73], [73], [73], [73], [73]. Service: 08/26/2024 by email. [1027775] [23-2218] [Deanne Maynard] [Entered: 08/26/2024 09:22 PM] (13) |
| Aug 26, 2024 | 77 | Confidential Novartis Pharmaceuticals Corporation's Response to Bond Request filed by Appellant Novartis Pharmaceuticals Corporation corresponding to Doc. No. [76]. Service: 08/26/2024 by email. [1027776] [23-2218] [Deanne Maynard] [Entered: 08/26/2024 09:26 PM] (0) |
| Aug 23, 2024 | 74 | NOTICE OF ORAL ARGUMENT. Panel: 2411A. Case scheduled November 13, 2024. Response to Notice of Oral Argument due: 09/06/2024. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [1027288] [MJL] [Entered: 08/23/2024 10:29 AM] (2) |
| Aug 22, 2024 | 72 | ORDER filed deconsolidating appeals; Appeal No. 2023-2219 is deconsolidated from Appeal Nos. 2023-2218, 2023-2220, and 2023-2221. The revised official captions are reflected in the order. The motion for limited remand [58] is granted to the limited extent explained in the order. This court retains jurisdiction over Appeal Nos. 2023-2218 and 2023-2219. Novartis and Torrent shall inform this court within three days after the district court's resolution of their motion whether Torrent continues to participate in Appeal No. 2023-2218 and whether Appeal No. 2023-2219 is to be dismissed. (Per Curiam). Service as of this date by the Clerk of Court. [1026975] [23-2218, 23-2219] [NL] [Entered: 08/22/2024 10:54 AM] (4) |
| Aug 22, 2024 | 73 | ORDER filed This court's 08/14/2024 orders in the captioned appeals remain in effect pending further notice of the court. If the D.C. Circuit modifies its 08/19/2024 order, the parties are directed to notify this court no later than 1 day thereafter. Appeal Nos. 2023-2218 et al. and Appeal No. 2024-2211 shall be considered companion cases and assigned to the same merits panel. The motions to waive Federal Circuit Rule 25.1(d) ([62], [67], [1024755-2], [1025785-2], & [1026149-2]) as to the Rule 8 motion papers are granted.; The motions to expedite are granted to the extent that, for Appeal No. 2024-2211, the response brief is due no later than 08/27/2024; the reply brief is due no later than 08/30/2024; and the joint appendix is due no later than 09/02/2024. Oral argument will be addressed separately. Within three days from the date of entry of this order, Novartis is directed to respond to MSN's bond request. See Appeal No. 2023-2218, ECF No. [69]-1 at 30; Appeal No. 2024-2211, ECF No. [1025787-2]-1 at 33-34. MSN may reply within three days thereafter. (Per Curiam). Service as of this date by the Clerk of Court. [1026989] [23-2218, 24-2211] [NL] [Entered: 08/22/2024 11:52 AM] (4) |
| Aug 19, 2024 | 70 | REPLY of Appellant Novartis Pharmaceuticals Corporation to response [68]. Service: 08/19/2024 by email. [1026143] [23-2218] [Deanne Maynard] [Entered: 08/19/2024 10:36 PM] (22) |
| Aug 19, 2024 | 71 | Confidential REPLY in Support of Emergency Motion for Injunction Pending Appeal and to Expedite filed by Appellant Novartis Pharmaceuticals Corporation corresponding to Doc. No. [70]. Service: 08/19/2024 by email. [1026144] [23-2218] [Deanne Maynard] [Entered: 08/19/2024 10:40 PM] (0) |
| Aug 16, 2024 | 66 | Notice from Appellant Novartis Pharmaceuticals Corporation regarding conflicts with oral argument. Service: 08/16/2024 by email. [1025631] [23-2218] [Deanne Maynard] [Entered: 08/16/2024 12:57 PM] (5) |
| Aug 16, 2024 | 67 | MOTION of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to waive confidentiality requirements. Service: 08/16/2024 by email. [1025788] [23-2218] [Ronald Daignault] [Entered: 08/16/2024 09:57 PM] (57) |
| Aug 16, 2024 | 68 | RESPONSE of Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. to Doc No. [63], [63]. Service: 08/16/2024 by email. [1025789] [23-2218] [Ronald Daignault] [Entered: 08/16/2024 10:02 PM] (66) |
| Aug 16, 2024 | 69 | Confidential Defendants-Appellees' Opposition To Novartis' Emergency Motion For Injunction Pending Appeal And To Expedite filed by Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. corresponding to Doc. No. [68]. Service: 08/16/2024 by email. [1025790] [23-2218] [Ronald Daignault] [Entered: 08/16/2024 10:15 PM] (0) |
| Aug 14, 2024 | 65 | ORDER MSN is directed to respond to Novartisâ??s motion no later than 08/16/2024, and any reply is due no later than 08/19/2024. MSN is temporarily enjoined from commercial marketing and sale of their generic version of Entresto® while the court considers the Rule 8 motion [63]. (Per Curiam). Service as of this date by the Clerk of Court. [1025084] [NL] [Entered: 08/14/2024 05:10 PM] (3) |
| Aug 13, 2024 | 62 | MOTION of Appellant Novartis Pharmaceuticals Corporation to waive confidentiality requirements. Service: 08/13/2024 by email. [1024679] [23-2218] [Deanne Maynard] [Entered: 08/13/2024 03:29 PM] (54) |
| Aug 13, 2024 | 63 | MOTION of Appellant Novartis Pharmaceuticals Corporation for an emergency stay pending appeal under Rule 8/18, to expedite hearing. Service: 08/13/2024 by email. [1024689] [23-2218] [Deanne Maynard] [Entered: 08/13/2024 03:45 PM] (76) |
| Aug 13, 2024 | 64 | Confidential MOTION for an emergency stay pending appeal under Rule 8/18, to expedite hearing filed by Appellant Novartis Pharmaceuticals Corporation corresponding to Doc. No. [63], corresponding to Doc. No. [63]. Service: 08/13/2024 by email. [1024696] [23-2218] [Deanne Maynard] [Entered: 08/13/2024 03:57 PM] (0) |
| Aug 6, 2024 | 61 | ORDER The revised official caption in Appeal No. 2023-2218 and 2023-2221 is reflected in this order. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221. Service as of this date by the Clerk of Court. [1023023] [23-2218, 23-2219, 23-2220, 23-2221] [LMS] [Entered: 08/06/2024 10:04 AM] (3) |
| Aug 2, 2024 | 60 | Joint Stipulation of Voluntary Dismissal for Appellant Novartis Pharmaceuticals Corporation and Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III and Hetero USA, Inc.. Service: 08/02/2024 by email. [1022403] [23-2218] [Deanne Maynard] [Entered: 08/02/2024 12:56 PM] (9) |
| Jul 30, 2024 | 59 | ORDER filed granting the motion [57] to the limited extent explained in the order. This court retains jurisdiction over Appeal Nos. 2023-2218 and 2023-2221. Proceedings in these consolidated cases are stayed. Novartis and Hetero shall inform this court within three days after the district court's resolution of their motion whether Hetero continues to participate in Appeal Nos. 2023-2218 and 2023-2221. Service as of this date by the Clerk of Court. [1021410] [23-2218, 23-2219, 23-2220, 23-2221] [LMS] [Entered: 07/30/2024 12:33 PM] (3) |
| Jul 13, 2024 | 58 | MOTION of Appellant Novartis Pharmaceuticals Corporation and Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. for limited remand. Service: 07/13/2024 by email. [1017549] [23-2218] [Deanne Maynard] [Entered: 07/13/2024 12:41 PM] (16) |
| Jun 27, 2024 | 57 | MOTION of Appellant Novartis Pharmaceuticals Corporation and Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III and Hetero USA, Inc. for limited remand. Service: 06/27/2024 by email. [1014096] [23-2218] [Deanne Maynard] [Entered: 06/27/2024 04:51 PM] (16) |
| May 29, 2024 | 56 | The following conflict dates submitted by Ms. Deanne Maynard for Novartis Pharmaceuticals Corporation have been accepted by the court: 10/07/2024, 10/08/2024, 10/09/2024, 10/10/2024, 10/11/2024. [1007275]--[Edited 05/29/2024 by JCP to correct month of conflict] [JCP] [Entered: 05/29/2024 04:31 PM] (0) |
| May 22, 2024 | 55 | Notice from Appellant Novartis Pharmaceuticals Corporation regarding conflicts with oral argument. Service: 05/22/2024 by email. [1005914] [23-2218] [Deanne Maynard] [Entered: 05/22/2024 03:11 PM] (5) |
| Apr 30, 2024 | 54 | Official caption revised to reflect the dismissal of 23-2260 (see attached). Service as of this date by the Clerk of Court. [1000911] [GWK] [Entered: 04/30/2024 11:55 AM] (2) |
| Mar 10, 2024 | 0 | IN RE: ENTRESTO (SACUBITRIL/VALSARTAN) [ORDER] [nonprecedential] (0) |
| Mar 6, 2024 | 53 | ORDER deconsolidating Appeal No. 2023-2260 from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221, and dismissing Appeal No. 2023-2260.; Each side shall bear its own costs regarding Appeal No. 2023-2260. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221.; issuing mandate as to Appeal No. 2023-2260 only. Service as of this date by the Clerk of Court. [988615] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 03/06/2024 09:45 AM] (3) |
| Feb 28, 2024 | 52 | Joint Stipulation of Voluntary Dismissal for Appellant Novartis Pharmaceuticals Corporation Appellee Mylan Pharmaceuticals Inc.. Service: 02/28/2024 by email. [987118] [23-2218] [Deanne Maynard] [Entered: 02/28/2024 09:56 AM] (9) |
| Feb 22, 2024 | 51 | ORDER filed granting the motion [42] to the limited extent explained in the order.; This court retains jurisdiction over Appeal No. 2023-2260. Proceedings in these consolidated cases are stayed. Novartis and Mylan shall inform this court within three days after the district court's resolution of their motion whether Appeal No. 2023-2260 is to be dismissed. Service as of this date by the Clerk of Court. [985658] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 02/22/2024 12:15 PM] (4) |
| Feb 14, 2024 | 50 | The following conflict dates submitted by Ronald M Daignault for MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc. and MSN Life Sciences Private Ltd. have been accepted by the court: 07/08/2024, 07/09/2024, 07/10/2024, 07/11/2024, 07/12/2024, 08/05/2024, 08/06/2024, 08/07/2024, 08/08/2024, 08/09/2024. [983673] [MJL] [Entered: 02/14/2024 08:48 AM] (0) |
| Feb 13, 2024 | 49 | The following conflict dates submitted by Deanne Maynard for Novartis Pharmaceuticals Corporation have been accepted by the court: 07/08/2024, 07/09/2024, 07/10/2024, 07/11/2024, 07/12/2024. [983544] [MJL] [Entered: 02/13/2024 03:44 PM] (0) |
| Feb 8, 2024 | 44 | Notice from Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. and Appellant Novartis Pharmaceuticals Corporation regarding conflicts with oral argument. Service: 02/08/2024 by email. [982426] [23-2218] [Dmitry Shelhoff] [Entered: 02/08/2024 10:24 AM] (2) |
| Feb 8, 2024 | 45 | Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. Service: 02/08/2024 by email. [982637] [23-2218] [Robert Florence] [Entered: 02/08/2024 04:04 PM] (2) |
| Feb 8, 2024 | 46 | Notice from Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 02/08/2024 by email. [982709] [23-2218] [Ronald Daignault] [Entered: 02/08/2024 07:04 PM] (3) |
| Feb 7, 2024 | 43 | Notice from Appellant Novartis Pharmaceuticals Corporation regarding conflicts with oral argument. Service: 02/07/2024 by email. [982111] [23-2218] [Deanne Maynard] [Entered: 02/07/2024 09:54 AM] (5) |
| Feb 7, 2024 | 48 | 6 paper copies of Doc. No. [39], [38], [37] received from Appellant Novartis Pharmaceuticals Corporation. [983534] [VDW] [Entered: 02/13/2024 03:37 PM] (0) |
| Feb 5, 2024 | 47 | 6 paper copies of Doc. No. [29] received from Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. [983292] [VDW] [Entered: 02/13/2024 10:08 AM] (0) |
| Feb 2, 2024 | 42 | MOTION of Appellant Novartis Pharmaceuticals Corporation and Appellee Mylan Pharmaceuticals Inc. for limited remand. Service: 02/02/2024 by email. [981228] [23-2218] [Deanne Maynard] [Entered: 02/02/2024 10:25 AM] (16) |
| Feb 1, 2024 | 40 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [981048] [GWK] [Entered: 02/01/2024 02:20 PM] (0) |
| Feb 1, 2024 | 41 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [981049] [GWK] [Entered: 02/01/2024 02:22 PM] (1) |
| Jan 25, 2024 | 37 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 01/25/2024 by email. [979276]--[Edited 02/01/2024 by GWK - compliance review complete] [Deanne Maynard] [Entered: 01/25/2024 12:47 PM] (122) |
| Jan 25, 2024 | 38 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 01/25/2024 by email. [979279]--[Edited 02/01/2024 by GWK - compliance review complete] [Deanne Maynard] [Entered: 01/25/2024 12:53 PM] (43) |
| Jan 25, 2024 | 39 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 01/25/2024 by email. [979284] --[Edited 02/01/2024 by GWK - compliance review complete] [Deanne Maynard] [Entered: 01/25/2024 01:09 PM] (2029) |
| Jan 24, 2024 | 36 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Novartis Pharmaceuticals Corporation, Opening Brief, Reply Brief, Appendix [18], [32], [33], is not in compliance with the rules of this court (see attached). Compliant documents due on 01/31/2024. Service as of this date by the Clerk of Court. [979048] [GWK] [Entered: 01/24/2024 03:24 PM] (2) |
| Jan 17, 2024 | 33 | APPENDIX FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 01/17/2024 by email. [977140] [23-2218] This document is non-compliant. See Doc No. [36] [Deanne Maynard] [Entered: 01/17/2024 02:31 PM] (2029) |
| Jan 17, 2024 | 34 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellant Novartis Pharmaceuticals Corporation. Service: 01/17/2024 by email. [977145] [23-2218] [Deanne Maynard] [Entered: 01/17/2024 02:38 PM] (2) |
| Jan 17, 2024 | 35 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 01/17/2024 by email. [977231] [23-2218] [Dmitry Shelhoff] [Entered: 01/17/2024 05:24 PM] (3) |
| Jan 10, 2024 | 32 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 01/10/2024 by email. [975859] This document is non-compliant. See Doc No. [36] [Deanne Maynard] [Entered: 01/10/2024 02:55 PM] (43) |
| Dec 8, 2023 | 31 | ORDER granting motion to extend time to file brief [26] filed by Appellant Novartis Pharmaceuticals Corporation. The reply brief is due 01/10/2024. Service as of this date by the Clerk of Court. [968920] [LMS] [Entered: 12/08/2023 02:27 PM] (3) |
| Dec 1, 2023 | 30 | REPLY of Appellant Novartis Pharmaceuticals Corporation to response [28]. Service: 12/01/2023 by email. [966831] [23-2218] [Deanne Maynard] [Entered: 12/01/2023 09:26 AM] (9) |
| Nov 30, 2023 | 27 | NOTICE OF NON-COMPLIANCE: The submission of Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd., Response Brief [22], is not in compliance with the rules of this court (see attached). Compliant document due on 12/07/2023. Service as of this date by the Clerk of Court. [966750] [MMA] [Entered: 11/30/2023 04:33 PM] (2) |
| Nov 30, 2023 | 28 | RESPONSE of Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. and Appellant Novartis Pharmaceuticals Corporation to Doc No. [26]. Service: 11/30/2023 by email. [966769] [23-2218] [Dmitry Shelhoff] [Entered: 11/30/2023 05:06 PM] (14) |
| Nov 30, 2023 | 29 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. Service: 11/30/2023 by email. [966782] --[Edited 12/15/2023 by MMA - Reason: compliance review complete] [Ronald Daignault] [Entered: 11/30/2023 05:39 PM] (79) |
| Nov 29, 2023 | 26 | MOTION of Appellant Novartis Pharmaceuticals Corporation to extend the time to 01/10/2024 to file brief. Service: 11/29/2023 by email. [966165] [23-2218] [Deanne Maynard] [Entered: 11/29/2023 10:09 AM] (9) |
| Nov 21, 2023 | 25 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [24], Doc No. [23], Doc No. [21], Doc No. [20], ERROR: Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Certificates of Interest [20], [23] and Notices of Related Case Information [21], [24] incomplete case numbers. CORRECTION: Please include all consolidated case numbers on future filings. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [965015] [JSP] [Entered: 11/21/2023 02:42 PM] (0) |
| Nov 20, 2023 | 20 | Amended Certificate of Interest for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 11/20/2023 by email. [964651] [23-2218] [Ronald Daignault] [Entered: 11/20/2023 04:48 PM] (3) |
| Nov 20, 2023 | 21 | Notice of Related Case Information for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 11/20/2023 by email. [964657] [23-2218] [Ronald Daignault] [Entered: 11/20/2023 04:52 PM] (4) |
| Nov 20, 2023 | 22 | RESPONSE BRIEF FILED by Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 11/20/2023 by email. [964661] [23-2218] This document is non-compliant. See Doc No. [27] [Ronald Daignault] [Entered: 11/20/2023 05:03 PM] (79) |
| Nov 20, 2023 | 23 | Amended Certificate of Interest for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 11/20/2023 by email. [964665] [23-2218] [Dmitry Shelhoff] [Entered: 11/20/2023 05:19 PM] (3) |
| Nov 20, 2023 | 24 | Notice of Related Case Information for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 11/20/2023 by email. [964667] [23-2218] [Dmitry Shelhoff] [Entered: 11/20/2023 05:24 PM] (4) |
| Oct 12, 2023 | 19 | Note to File: The following cases are consolidated: 23-2218 (Lead) with 23-2219, 23-2220, 23-2221, 23-2260 (Member Cases). The parties must file all documents in the lead appeal only. [956044] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [MMA] [Entered: 10/12/2023 04:57 PM] (0) |
| Oct 10, 2023 | 18 | MODIFIED ENTRY: OPENING BRIEF FILED by Appellant Novartis Pharmaceuticals Corporation. Service: 10/10/2023 by email. [955433] This document is non-compliant. See Doc No. [36] [Deanne Maynard] [Entered: 10/10/2023 06:14 PM] (122) |
| Oct 6, 2023 | 17 | Official caption revised to reflect Alembic's non-participation. (see attached). Service as of this date by the Clerk of Court. [955034] [MMA] [Entered: 10/06/2023 02:15 PM] (3) |
| Aug 24, 2023 | 16 | ORDER granting the motions [15] [943725-2] to the extent that the appeals are consolidated, and thus one set of briefs should be filed for the five appeals. The revised official caption is reflected above. Appellant's opening brief is due no later than October 10, 2023. Absent objection within seven days from the date of entry of this order, the court will revise the official caption to reflect Alembic's non-participation in these appeals. Service as of this date by the Clerk of Court. [945715] [23-2218, 23-2219, 23-2220, 23-2221, 23-2260] [LMS] [Entered: 08/24/2023 03:12 PM] (3) |
| Aug 16, 2023 | 15 | MOTION of Appellant Novartis Pharmaceuticals Corporation to consolidate appeals (23-2218, 23-2219, 23-2220, 23-2221, and 23-2260). Service: 08/16/2023 by email. [943720] [23-2218] [Deanne Maynard] [Entered: 08/16/2023 05:34 PM] (18) |
| Aug 14, 2023 | 3 | Entry of Appearance for Dmitry V. Shelhoff; Kenneth S. Canfield; Edward D. Pergament; Julia S. Kim as counsel for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 08/14/2023 by email. [942777] [23-2218] [Dmitry Shelhoff] [Entered: 08/14/2023 01:32 PM] (2) |
| Aug 14, 2023 | 4 | Certificate of Interest for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 08/14/2023 by email. [942778] [23-2218] [Dmitry Shelhoff] [Entered: 08/14/2023 01:34 PM] (3) |
| Aug 14, 2023 | 5 | Docketing Statement for the Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 08/14/2023 by email. [942779] [23-2218] [Dmitry Shelhoff] [Entered: 08/14/2023 01:36 PM] (2) |
| Aug 14, 2023 | 6 | Notice of Related Case Information for Appellees Hetero Labs Limited, Hetero Labs Limited Unit-III, Hetero USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.. Service: 08/14/2023 by email. [942780] [23-2218] [Dmitry Shelhoff] [Entered: 08/14/2023 01:37 PM] (2) |
| Aug 14, 2023 | 7 | Entry of Appearance for Ronald M. Daignault; Richard Juang as counsel for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 08/14/2023 by email. [942788] [23-2218] [Ronald Daignault] [Entered: 08/14/2023 01:47 PM] (1) |
| Aug 14, 2023 | 8 | Certificate of Interest for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 08/14/2023 by email. [942790] [23-2218] [Ronald Daignault] [Entered: 08/14/2023 01:50 PM] (3) |
| Aug 14, 2023 | 9 | Docketing Statement for the Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 08/14/2023 by email. [942794] [23-2218] [Ronald Daignault] [Entered: 08/14/2023 01:51 PM] (2) |
| Aug 14, 2023 | 10 | Notice of Related Case Information for Appellees MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals, Inc.. Service: 08/14/2023 by email. [942795] [23-2218] [Ronald Daignault] [Entered: 08/14/2023 01:53 PM] (4) |
| Aug 14, 2023 | 11 | Entry of Appearance for Nicholas N. Kallas; Christina Schwarz as counsel for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942917] [23-2218] [Deanne Maynard] [Entered: 08/14/2023 05:28 PM] (2) |
| Aug 14, 2023 | 12 | Certificate of Interest for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942923] [23-2218] [Deanne Maynard] [Entered: 08/14/2023 05:34 PM] (2) |
| Aug 14, 2023 | 13 | Docketing Statement for the Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942925] [23-2218] [Deanne Maynard] [Entered: 08/14/2023 05:37 PM] (3) |
| Aug 14, 2023 | 14 | Notice of Related Case Information for Appellant Novartis Pharmaceuticals Corporation. Service: 08/14/2023 by email. [942926] [23-2218] [Deanne Maynard] [Entered: 08/14/2023 05:40 PM] (4) |
| Aug 2, 2023 | 2 | Entry of Appearance for Deanne E. Maynard; Seth W. Lloyd as counsel for Appellant Novartis Pharmaceuticals Corporation. Service: 08/02/2023 by email. [940085] [23-2218] [Deanne Maynard] [Entered: 08/02/2023 11:49 AM] (1) |
| Jul 31, 2023 | 1 | Appeal docketed. Received: 07/25/2023. [939660]Entry of Appearance due 08/14/2023. Certificate of Interest is due on 08/14/2023. Docketing Statement due 08/14/2023. Appellant's brief is due 09/29/2023. [MMA] [Entered: 07/31/2023 05:39 PM] (106) |
